Mechanistic Investigations Support Liver Safety of Ubrogepant

Keyphrases

• Liver Safety 100%
• Mechanistic Investigation 100%
• Ubrogepant 100%
• Telcagepant 66%
• MK-3207 66%
• Calcitonin Gene-related Peptide 50%
• Hepatotoxicity 50%
• DILIsym 50%
• Liver Toxicity 33%
• Clinical Trials 33%
• Dosing Regimen 16%
• Clinical Development 16%
• Migraine Treatment 16%
• Dose Effect 16%
• Therapeutic Efficacy 16%
• Drug Exposure 16%
• Oxidative Stress 16%
• Liver Cells 16%
• Small Molecules 16%
• Mitochondrial Dysfunction 16%
• Daily Dose 16%
• Mechanistic Studies 16%
• Low Potential 16%
• Structural Modification 16%
• Clinical Dose 16%
• Reactive Metabolites 16%
• Drug-induced Liver Injury 16%
• Quantitative Systems Toxicology 16%
• Trial Experience 16%
• Bile Acid Homeostasis 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Ubrogepant 100%
• Hepatotoxicity 83%
• Telcagepant 66%
• Calcitonin Gene Related Peptide Receptor Antagonist 50%
• Clinical Trial 33%
• Combination Therapy 16%
• Migraine 16%
• Toxic Hepatitis 16%
• Bile Acid 16%
• Systems Toxicology 16%